MondegarAI
B Group, Inc.

Q3 2025 · 13F-HR

B Group, Inc.holdings as filed

Filed 2025-11-14 · accession 0001420506-25-003231

$135.9M
Reported value
20
Positions
2025-09-30
Period end
View analyzed profile →PRO

The Brief · B Group, Inc. · Q3 2025

AI · grounded in 13F

B Group, Inc. established a new position in ADMA valued at $35.4M. The fund also initiated new stakes in LLY for $17.2M and NVDA for $14M. Additional new positions include ZLAB at $13.6M and AKRO at $11M.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
000899104ADMAADMA BIOLOGICS INC$35.4M26.0%2,412,542CommonSOLE
532457108LLYELI LILLY & CO$17.2M12.6%22,500PUTSOLE
67066G104NVDANVIDIA CORPORATION$14.0M10.3%75,000PUTSOLE
98887Q104ZLABZAI LAB LTD$13.6M9.97%400,000CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$11.0M8.12%232,446CommonSOLE
15117K103CLLSCELLECTIS S A$9.4M6.88%3,281,501CommonSOLE
877619106TSHATAYSHA GENE THERAPIES INC$5.9M4.33%1,800,556CommonSOLE
045396207ASMBASSEMBLY BIOSCIENCES INC$4.5M3.31%175,706CommonSOLE
629444118NRXPWNRX PHARMACEUTICALS INC$4.5M3.28%3,000,000CommonSOLE
90400D108RAREULTRAGENYX PHARMACEUTICAL IN$4.1M2.99%135,000CommonSOLE
05153U107AURAAURA BIOSCIENCES INC$3.5M2.60%572,576CommonSOLE
462260100IOVAIOVANCE BIOTHERAPEUTICS INC$3.3M2.39%1,500,000CommonSOLE
82657M105SGHTSIGHT SCIENCES INC$3.2M2.35%930,000CommonSOLE
00773J202SYRESPYRE THERAPEUTICS INC$1.7M1.23%100,000CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$1.7M1.23%31,500CommonSOLE
687604108ORKAORUKA THERAPEUTICS INC$1.4M1.06%75,000CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$1.4M1.02%35,000CommonSOLE
76029N106REPLREPLIMUNE GROUP INC$209,5000.15%50,000CALLSOLE
36468G103GAMEGAMESQUARE HLDGS INC$169,7000.12%250,000CommonSOLE
457669307INSMINSMED INC$22,7540.02%158CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.